Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2016
Introducing a common CADTH recommendation framework and establishing a minimum period of 120 calendar days for advance notification of anticipated submissions and resubmissions for CADTH Common Drug Review and pan-Canadian Oncology Drug Review Programs
23 March 2016 - CADTH will be implementing changes to the CDR Procedures and pCODR Procedures that will require all manufacturers/submitters ...
Posted by Michael Wonder on 24 Mar 2016
CADTH calls for patient input on a submission from Takeda for Entyvio (vedolizumab)
23 March 2016 - CADTH has received the following notice of a pending submission from Takeda for Entyvio (vedolizumab) for use ...
Posted by Michael Wonder on 23 Mar 2016
CADTH calls for patient input on a submission from Gilead for sofosbuvir with velpatasvir
23 March 2016 - CADTH has received notice of a pending submission from Gileda for sofosbuvir with velpatasvir for the treatment ...
Posted by Michael Wonder on 17 Mar 2016
Call for patient input on a submission from UCB for brivaracetam
17 March 2016 - CADTH has received notice of a pending submission from UCB for brivaracetam for the treatment of patients ...
Posted by Michael Wonder on 11 Mar 2016
Call for patient input on a submission from Hospira for a subsequent entry biologic
11 March 2016 - CADTH has received notice of a pending submission from Hospira for Inflectra (infliximab) for the treatment of ...
Posted by Michael Wonder on 09 Mar 2016
Call for patient input on a submission from Merck for a subsequent entry biologic
9 March 2016 - CADTH has received notice of a pending submission from Merck for etanercept for use by certain patients ...
Posted by Michael Wonder on 01 Mar 2016
CADTH to provide drug plans with copies of CDR submission or resubmission materials
25 February 2016 - CADTH has begun providing authorized recipients from the CDR-participating drug plans with copies of all category 1 ...
Posted by Michael Wonder on 28 Feb 2016
Revised procedure for providing CADTH review team’s responses
25 February 2016 - Effective for all submissions and resubmissions targeting the April 2016 CDEC meeting and onward, manufacturers will be ...
Posted by Michael Wonder on 26 Feb 2016
Update on procedures for the CADTH Common Drug Review and pan-Canadian Oncology Drug Review: mandatory disclosure of a submitted drug price
25 February 2016 - In late September 2015, CADTH invited stakeholder comments and feedback on proposed revisions to the CADTH Common ...
Posted by Michael Wonder on 23 Feb 2016
Call for feedback: new drugs for type 2 diabetes: a therapeutic review update
22 February 2016 - A proposed CADTH project scope on new drugs for type 2 diabetes mellitus: a therapeutic review update ...
Posted by Michael Wonder on 17 Feb 2016
CADTH calls for patient input on a new submission from Eli Lilly for ixekizumab
17 February 2016 - CADTH has received notice of a pending submission from Eli Lilly for ixekizumab for the treatment of ...
Posted by Michael Wonder on 17 Feb 2016
CADTH calls for patient input on a new submission from Actelion for Uptravi
16 February 2016 - CADTH has received notice of a pending submission from Actelion for Uptravi (selexipag) for the treatment of ...
Posted by Michael Wonder on 06 Feb 2016
CADTH calls for patient input on submissions for 2 new medicines for use by patients with HIV infection
5 February 2016 - CADTH has received notice of pending submissions from Theratechnologies for Egrifta (tesamorelin acetate) for lipodystrophy in HIV-infected ...
Posted by Michael Wonder on 03 Feb 2016
CADTH calls for patient input on a new submission from Janssen-Cilag for canagliflozin hemihydrate with metformin hydrochloride
3 February 2016 - CADTH has received notice of a pending submission from Janssen-Cilag for canagliflozin hemihydrate with metformin hydrochloride for ...
Posted by Michael Wonder on 01 Feb 2016
CADTH calls for patient input on a new submission from Genzyme for Cerdelga
1 February 2016 - CADTH has received notice of a pending submission from Genzyme for Cerdelga (eliglustat tartrate) for the treatment ...